He hui loea kūʻokoʻa ka PBAC i koho ʻia e ke Aupuni Australia. Loaʻa nā lālā i nā kauka, nā ʻoihana olakino, nā ʻekekema olakino a me nā ʻelele kūʻai.
ʻO kā lākou kuleana ʻo ka ʻōlelo ʻana i nā lāʻau lapaʻau hou no ka papa inoa ʻana ma ka papahana pono lāʻau lapaʻau (PBS). 'A'ole hiki ke helu 'ia ka lā'au lapa'au hou ke 'ole ke kōmike i ka mana'o maika'i. Hālāwai ka PBAC i ʻekolu manawa i ka makahiki, ʻo Malaki, Iulai a me Nowemapa.
I kēia ʻaoʻao:
Papahana halawai PBAC e hiki mai ana:
November 2020
Lymphoma a me CLL hoʻouna i ka papahana e hiki mai ana
ʻO Nowemapa 2020 lymphoma/CLL waiho ʻia ma ka papahana
| ʻAno hoʻouna | Ka inoa lāʻau a me ke kākoʻo | ʻAno lāʻau a hoʻohana | Noi ʻia ka papa inoa e ke kākoʻo & kumu |
| Papa inoa hou (ka hoʻouna liʻiliʻi) | Ibrutinib | Leukemia lymphocytic mau loa (CLL); lymphoma lymphocytic liʻiliʻi (SLL); Mantmph cell lymphoma | No ke noi ʻana i kahi mana Pono ka papa inoa o ka papa ibrutinib ma lalo o nā kūlana like me ka capsule i helu mua ʻia. |
| Papa inoa hou (ka hoʻouna liʻiliʻi) | Mogamulizumab (Kyowa Kirin) | ʻO lymphoma T-cell ʻili (CTCL) | Hoʻouna hou ʻia no ke noi ʻana i kahi Pauku 100 (ke kālā kūpono o ka chemotherapy) Mana Mana e koi ʻia no nā poʻe maʻi me CTCL i hoʻihoʻi a i ʻole refractory i mālama mua ʻia me hoʻokahi lāʻau lapaʻau ma mua. |
Nā hopena o ka hālāwai PBAC
July 2020
Lymphoma a me CLL hoʻouna a me nā hopena
Iulai 2020 PBAC nā hualoaʻa hālāwai no lymphoma a me CLL hoʻouna
| ʻO ka lāʻau lapaʻau, kākoʻo, ʻano hoʻouna | ʻAno lāʻau a hoʻohana paha | Noi ʻia ka papa inoa e ke kākoʻo/ke kumu o ka waiho ʻana | Ka hopena PMAC |
Venetoclax (AbbVie) Hoʻololi i ka papa inoa (hoʻouna liʻiliʻi) | Leukemia lymphocytic mau (CLL) | Hoʻouna hou ʻia e noi i kahi papa inoa Mana Mana, i hui pū ʻia me Obinutuzumab, no ka lāʻau lapaʻau mua o nā maʻi me CLL i loaʻa nā kūlana like no ka fludarabine based chemotherapy. | Manaʻo ka PBAC i ka papa inoa o ka venetoclax i hui pū ʻia me ka obinutuzumab no ka lāʻau lapaʻau mua o nā maʻi me CLL i loaʻa nā kūlana noho like ʻole a kūpono ʻole no ka fludarabine based chemo immunotherapy. |
| Acalabrutinib (AstraZeneca) | Leukemia lymphocytic mau loa (CLL) a i ʻole lymphocytic lymphoma liʻiliʻi (SLL) | No ke noi ʻana i kahi papa inoa Manaʻo no ka mālama ʻana i nā maʻi (ma ke ʻano he monotherapy a i hui pū ʻia me ka obinutuzumab) me CLL a i ʻole SLL i mālama ʻole ʻia ma mua i manaʻo ʻia ʻaʻole kūpono no ka mālama ʻana me kahi analogue purine. ʻO kahi noi ʻelua no ka hoʻohana wale ʻana i ka subgroup o nā maʻi me kahi holoi 17p. | ʻAʻole i hana ka PBAC E paipai i ka papa inoa o ka acalabrutinib, no ka hoʻohana ʻana ma ke ʻano he monotherapy a i hui pū ʻia me ka obinutuzumab, no ka lāʻau lapaʻau mua o nā maʻi me CLL a i ʻole SLL i manaʻo ʻia ʻaʻole kūpono no ka mālama ʻana me kahi analogue purine. Ua noʻonoʻo ka PBAC ʻaʻole i ʻae ʻia ke kiʻekiʻe o ke kumukūʻai hoʻonui ʻia a maopopo ʻole i ke kumu kūʻai. |
Mogamulizumab (Kyowa Kirin) | ʻO lymphoma T-cell ʻili (CTCL) | No ke noi ʻana i kahi papa inoa o ka Pauku 100 (Efficient Funding of Chemotherapy) Authority Manaʻo (Kākau) no nā poʻe maʻi me ka CTCL i hoʻihoʻi ʻia a i ʻole refractory i mālama mua ʻia me ka liʻiliʻi o hoʻokahi lāʻau lapaʻau ma mua. | ʻAʻole ʻōlelo ka PBAC i ka papa inoa o ka mogamulizumab no ka mālama ʻana i nā poʻe maʻi me ka CTCL relapsed a refractory ma hope o hoʻokahi lāʻau lapaʻau ma mua o kēia maʻi. Ua manaʻo ka PBAC ʻaʻole maopopo ka nui o ka pōmaikaʻi no ka mogamulizumab e pili ana i ka holomua o ke ola manuahi a me ke ola holoʻokoʻa. Eia hou, ua noʻonoʻo ka PBAC ʻaʻole i ʻae ʻia ke kiʻekiʻe o ke kumukūʻai hoʻonui ʻia a maopopo ʻole i ke kumukūʻai i manaʻo ʻia, a ʻaʻole maopopo ka hopena kālā i manaʻo ʻia. |
ʻO Malaki 2020 PBAC ka papahana hālāwai no lymphoma/CLL & ke kali maikaʻi nei no ka hana mai Nowemapa 2019
| Ka inoa lāʻau a me ke kākoʻo | Subtype | Noi ʻia ka papa inoa a me ke kumu | Ka hopena PBAC |
| Ibrutinib (Janssen) | Leukemia lymphocytic mau loa (CLL) a i ʻole lymphocytic lymphoma liʻiliʻi (SLL) | Hoʻouna hou ʻia e noi i ka uku hou PBS no ka mālama ʻana iā CLL a i ʻole SLL me nā hōʻike o hoʻokahi a ʻoi aku paha ka holoi ʻana o ka chromosome 17p | Manaʻo ʻo PBAC i ka papa inoa PBS o ibrutinib no ka lāʻau lapaʻau mua me CLL/SLL me ka holoi ʻana 17p -ke kali nei no ka papa inoa ʻana, mai Nowemapa 2019 |
| Acalabrutinib (AstraZeneca) | Leukemia lymphocytic mau loa (CLL) a i ʻole lymphocytic lymphoma liʻiliʻi (SLL) | No ke noi ʻana i ka papa inoa PBS no ka mālama ʻana i nā mea maʻi me ka CLL a i ʻole refractory CLL a i ʻole SLL kūpono ʻole no ka mālama ʻana me kahi analogue purine. | Manaʻo ʻo PBAC i ka papa inoa o acalabrutinib no ka mālama ʻana i nā maʻi me R / R CLL / SLL i ka lāʻau lapaʻau lua - e kali ana e helu ʻia ʻo PBS mai Malaki 2020 |
| Pembrolizumab (MSD) | ʻO ka lymphoma B-cell mediastinal mua (PMBCL) | Hoʻouna hou ʻia e noi i ka papa inoa PBS no ka mālama ʻana i ka PMBCL i hoʻihoʻi ʻia a i ʻole refractory | Manaʻo ʻo PBAC i ka papa inoa PBS o pembrolizumab no R/R PMBCL - wke manaʻo nei e hoʻopaʻa inoa ʻia ʻo PBS mai Malaki 2020 |
